Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 227

1.

Detection and localisation of primary prostate cancer using 68 Ga-PSMA PET/CT compared with mpMRI and radical prostatectomy specimens.

Kalapara AA, Nzenza T, Pan HY, Ballok Z, Ramdave S, O'Sullivan R, Ryan A, Cherk M, Hofman MS, Konety BR, Lawrentschuk N, Bolton D, Murphy DG, Grummet JP, Frydenberg M.

BJU Int. 2019 Jul 1. doi: 10.1111/bju.14858. [Epub ahead of print]

PMID:
31260602
2.

Establishing a cryopreservation protocol for patient-derived xenografts of prostate cancer.

Porter LH, Lawrence MG, Wang H, Clark AK, Bakshi A, Obinata D, Goode D, Papargiris M, Mural, Clouston D, Ryan A, Norden S, Corey E, Nelson PS, Isaacs JT, Grummet J, Kourambas J, Sandhu S, Murphy DG, Pook D, Frydenberg M, Taylor RA, Risbridger GP.

Prostate. 2019 Aug;79(11):1326-1337. doi: 10.1002/pros.23839. Epub 2019 Jun 18.

PMID:
31212368
3.

Fractionated stereotactic body radiotherapy for up to five prostate cancer oligometastases: Interim outcomes of a prospective clinical trial.

Bowden P, See AW, Frydenberg M, Haxhimolla H, Costello AJ, Moon D, Ruljancich P, Grummet J, Crosthwaite A, Pranavan G, Peters JS, So K, Gwini SM, McKenzie DP, Nolan S, Smyth LML, Everitt C.

Int J Cancer. 2019 Jun 14. doi: 10.1002/ijc.32509. [Epub ahead of print]

PMID:
31199504
4.

Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer.

Davis ID, Martin AJ, Stockler MR, Begbie S, Chi KN, Chowdhury S, Coskinas X, Frydenberg M, Hague WE, Horvath LG, Joshua AM, Lawrence NJ, Marx G, McCaffrey J, McDermott R, McJannett M, North SA, Parnis F, Parulekar W, Pook DW, Reaume MN, Sandhu SK, Tan A, Tan TH, Thomson A, Tu E, Vera-Badillo F, Williams SG, Yip S, Zhang AY, Zielinski RR, Sweeney CJ; ENZAMET Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group.

N Engl J Med. 2019 Jul 11;381(2):121-131. doi: 10.1056/NEJMoa1903835. Epub 2019 Jun 2.

PMID:
31157964
5.

From indecision to precision: advances in imaging in metastatic prostate cancer.

Bolton D, Frydenberg M.

World J Urol. 2019 Jul;37(7):1237. doi: 10.1007/s00345-019-02820-9. No abstract available.

PMID:
31139907
6.

High ductal proportion predicts biochemical recurrence in prostatic ductal adenocarcinoma.

Harkin T, Elhage O, Chandra A, Khan N, Kiberu Y, Frydenberg M, Dasgupta P.

BJU Int. 2019 May 28. doi: 10.1111/bju.14831. [Epub ahead of print]

PMID:
31136054
7.

Exploring the impact of providing men with information about potential prostate cancer treatment options prior to receiving biopsy results.

Pillay B, Moon D, Meyer D, Crowe H, Mann S, Howard N, Wootten A, Frydenberg M.

Support Care Cancer. 2019 May 8. doi: 10.1007/s00520-019-04847-5. [Epub ahead of print]

PMID:
31065839
8.

Re: 68Ga-Labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography/Computed Tomography for Prostate Cancer: A Systematic Review and Meta-analysis.

Frydenberg M.

Eur Urol. 2019 Apr 4. pii: S0302-2838(19)30272-6. doi: 10.1016/j.eururo.2019.03.039. [Epub ahead of print] No abstract available.

PMID:
30955971
9.

Work after prostate cancer: a systematic review.

McLennan V, Ludvik D, Chambers S, Frydenberg M.

J Cancer Surviv. 2019 Apr;13(2):282-291. doi: 10.1007/s11764-019-00750-4. Epub 2019 Mar 21. Review.

PMID:
30900159
10.

Offspring Reports on Parental Place of Upbringing: Is It Valid?

Timm S, Schlünssen V, Benediktsdottir B, Bertelsen RJ, Bråbäck L, Holm M, Jogi R, Malinovschi A, Svanes C, Frydenberg M.

Epidemiology. 2019 May;30(3):e16-e18. doi: 10.1097/EDE.0000000000000988. No abstract available.

PMID:
30789435
11.

Asthma and selective migration from farming environments in a three-generation cohort study.

Timm S, Frydenberg M, Abramson MJ, Bertelsen RJ, Bråbäck L, Benediktsdottir B, Gislason T, Holm M, Janson C, Jogi R, Johannessen A, Kim JL, Malinovschi A, Mishra G, Moratalla J, Sigsgaard T, Svanes C, Schlünssen V.

Eur J Epidemiol. 2019 Jun;34(6):601-609. doi: 10.1007/s10654-019-00491-9. Epub 2019 Feb 7.

PMID:
30729356
12.

Suppressing fatty acid uptake has therapeutic effects in preclinical models of prostate cancer.

Watt MJ, Clark AK, Selth LA, Haynes VR, Lister N, Rebello R, Porter LH, Niranjan B, Whitby ST, Lo J, Huang C, Schittenhelm RB, Anderson KE, Furic L, Wijayaratne PR, Matzaris M, Montgomery MK, Papargiris M, Norden S, Febbraio M, Risbridger GP, Frydenberg M, Nomura DK, Taylor RA.

Sci Transl Med. 2019 Feb 6;11(478). pii: eaau5758. doi: 10.1126/scitranslmed.aau5758.

PMID:
30728288
13.

Reasons for Discontinuing Active Surveillance: Assessment of 21 Centres in 12 Countries in the Movember GAP3 Consortium.

Van Hemelrijck M, Ji X, Helleman J, Roobol MJ, van der Linden W, Nieboer D, Bangma CH, Frydenberg M, Rannikko A, Lee LS, Gnanapragasam VJ, Kattan MW; Members of the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance GAP3 consortium; Members of the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance GAP3 consortium.

Eur Urol. 2019 Mar;75(3):523-531. doi: 10.1016/j.eururo.2018.10.025. Epub 2018 Oct 29.

PMID:
30385049
14.

Robotic Assisted Radical Cystectomy vs Open Radical Cystectomy: Systematic Review and Meta-Analysis.

Sathianathen NJ, Kalapara A, Frydenberg M, Lawrentschuk N, Weight CJ, Parekh D, Konety BR.

J Urol. 2019 Apr;201(4):715-720. doi: 10.1016/j.juro.2018.10.006.

PMID:
30321551
15.

Parent Training for Preschool ADHD in Routine, Specialist Care: A Randomized Controlled Trial.

Lange AM, Daley D, Frydenberg M, Houmann T, Kristensen LJ, Rask C, Sonuga-Barke E, Søndergaard-Baden S, Udupi A, Thomsen PH.

J Am Acad Child Adolesc Psychiatry. 2018 Aug;57(8):593-602. doi: 10.1016/j.jaac.2018.04.014. Epub 2018 Jun 18.

PMID:
30071980
16.

Patient-derived Models of Abiraterone- and Enzalutamide-resistant Prostate Cancer Reveal Sensitivity to Ribosome-directed Therapy.

Lawrence MG, Obinata D, Sandhu S, Selth LA, Wong SQ, Porter LH, Lister N, Pook D, Pezaro CJ, Goode DL, Rebello RJ, Clark AK, Papargiris M, Van Gramberg J, Hanson AR, Banks P, Wang H, Niranjan B, Keerthikumar S, Hedwards S, Huglo A, Yang R, Henzler C, Li Y, Lopez-Campos F, Castro E, Toivanen R, Azad A, Bolton D, Goad J, Grummet J, Harewood L, Kourambas J, Lawrentschuk N, Moon D, Murphy DG, Sengupta S, Snow R, Thorne H, Mitchell C, Pedersen J, Clouston D, Norden S, Ryan A, Dehm SM, Tilley WD, Pearson RB, Hannan RD, Frydenberg M, Furic L, Taylor RA, Risbridger GP.

Eur Urol. 2018 Nov;74(5):562-572. doi: 10.1016/j.eururo.2018.06.020. Epub 2018 Jul 23.

PMID:
30049486
17.

Active surveillance of men with low risk prostate cancer: evidence from the Prostate Cancer Outcomes Registry-Victoria.

Evans MA, Millar JL, Earnest A, Frydenberg M, Davis ID, Murphy DG, Kearns PA, Evans SM.

Med J Aust. 2018 Jun 4;208(10):439-443. Epub 2018 May 28.

PMID:
29793403
18.

Can exercise delay transition to active therapy in men with low-grade prostate cancer? A multicentre randomised controlled trial.

Galvão DA, Hayne D, Frydenberg M, Chambers SK, Taaffe DR, Spry N, Scuffham PA, Ware RS, Hart NH, Newton RU.

BMJ Open. 2018 Apr 20;8(4):e022331. doi: 10.1136/bmjopen-2018-022331.

19.

Detection of glypican-1 (GPC-1) expression in urine cell sediments in prostate cancer.

Campbell DH, Lund ME, Nocon AL, Cozzi PJ, Frydenberg M, De Souza P, Schiller B, Beebe-Dimmer JL, Ruterbusch JJ, Walsh BJ.

PLoS One. 2018 Apr 19;13(4):e0196017. doi: 10.1371/journal.pone.0196017. eCollection 2018.

20.

Enduring epigenetic landmarks define the cancer microenvironment.

Pidsley R, Lawrence MG, Zotenko E, Niranjan B, Statham A, Song J, Chabanon RM, Qu W, Wang H, Richards M, Nair SS, Armstrong NJ, Nim HT, Papargiris M, Balanathan P, French H, Peters T, Norden S, Ryan A, Pedersen J, Kench J, Daly RJ, Horvath LG, Stricker P, Frydenberg M, Taylor RA, Stirzaker C, Risbridger GP, Clark SJ.

Genome Res. 2018 May;28(5):625-638. doi: 10.1101/gr.229070.117. Epub 2018 Apr 12.

21.

Experiences of Australian men diagnosed with advanced prostate cancer: a qualitative study.

Chambers SK, Hyde MK, Laurie K, Legg M, Frydenberg M, Davis ID, Lowe A, Dunn J.

BMJ Open. 2018 Feb 17;8(2):e019917. doi: 10.1136/bmjopen-2017-019917.

22.

Early Androgen Deprivation Therapy Improves Survival, But How Do We Determine in Whom?

Frydenberg M, Woo HH.

Eur Urol. 2018 Apr;73(4):519-520. doi: 10.1016/j.eururo.2018.01.004. Epub 2018 Jan 17. No abstract available.

PMID:
29373214
23.

Editorial Comment.

Frydenberg M.

J Urol. 2018 Feb;199(2):377. doi: 10.1016/j.juro.2017.08.128. Epub 2017 Nov 2. No abstract available.

PMID:
29104069
24.

Laparoscopic and robot-assisted vs open radical prostatectomy for the treatment of localized prostate cancer: a Cochrane systematic review.

Ilic D, Evans SM, Allan CA, Jung JH, Murphy D, Frydenberg M.

BJU Int. 2018 Jun;121(6):845-853. doi: 10.1111/bju.14062. Epub 2017 Nov 17.

25.

Intraductal carcinoma of the prostate can evade androgen deprivation, with emergence of castrate-tolerant cells.

Porter LH, Hashimoto K, Lawrence MG, Pezaro C, Clouston D, Wang H, Papargiris M, Thorne H, Li J; kConFab, Ryan A, Norden S, Moon D, Bolton DM, Sengupta S, Frydenberg M, Murphy DG, Risbridger GP, Taylor RA.

BJU Int. 2018 Jun;121(6):971-978. doi: 10.1111/bju.14043. Epub 2017 Oct 26.

26.

Comparison of perioperative, renal and oncologic outcomes in robotic-assisted versus open partial nephrectomy.

Tan JL, Frydenberg M, Grummet J, Hanegbi U, Snow R, Mann S, Begashaw K, Moon D.

ANZ J Surg. 2018 Mar;88(3):E194-E199. doi: 10.1111/ans.14154. Epub 2017 Sep 18.

PMID:
28922687
27.

Laparoscopic and robotic-assisted versus open radical prostatectomy for the treatment of localised prostate cancer.

Ilic D, Evans SM, Allan CA, Jung JH, Murphy D, Frydenberg M.

Cochrane Database Syst Rev. 2017 Sep 12;9:CD009625. doi: 10.1002/14651858.CD009625.pub2. Review.

28.

Age Related Differences in Responsiveness to Sildenafil and Tamsulosin are due to Myogenic Smooth Muscle Tone in the Human Prostate.

Lee SN, Chakrabarty B, Wittmer B, Papargiris M, Ryan A, Frydenberg M, Lawrentschuk N, Middendorff R, Risbridger GP, Ellem SJ, Exintaris B.

Sci Rep. 2017 Aug 31;7(1):10150. doi: 10.1038/s41598-017-07861-x.

29.

PSA testing for men at average risk of prostate cancer.

Armstrong BK, Barry MJ, Frydenberg M, Gardiner RA, Haines I, Carter SM.

Public Health Res Pract. 2017 Jul 26;27(3). pii: 2731721. doi: 10.17061/phrp2731721.

30.

Health-related quality of life for immediate versus delayed androgen-deprivation therapy in patients with asymptomatic, non-curable prostate cancer (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial.

Duchesne GM, Woo HH, King M, Bowe SJ, Stockler MR, Ames A, D'Este C, Frydenberg M, Loblaw A, Malone S, Millar J, Tai KH, Turner S.

Lancet Oncol. 2017 Sep;18(9):1192-1201. doi: 10.1016/S1470-2045(17)30426-6. Epub 2017 Jul 28.

PMID:
28760403
31.

Robotic prostatectomy took off, despite a lack of evidence and risks of inequity.

Frydenberg M, Gardiner RFA.

Med J Aust. 2017 Jul 17;207(2):90. No abstract available.

PMID:
28701134
32.

New Challenges in Psycho-Oncology Research III: A systematic review of psychological interventions for prostate cancer survivors and their partners: clinical and research implications.

Chambers SK, Hyde MK, Smith DP, Hughes S, Yuill S, Egger S, O'Connell DL, Stein K, Frydenberg M, Wittert G, Dunn J.

Psychooncology. 2017 Jul;26(7):873-913. doi: 10.1002/pon.4431. No abstract available.

33.

Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017.

Gillessen S, Attard G, Beer TM, Beltran H, Bossi A, Bristow R, Carver B, Castellano D, Chung BH, Clarke N, Daugaard G, Davis ID, de Bono J, Borges Dos Reis R, Drake CG, Eeles R, Efstathiou E, Evans CP, Fanti S, Feng F, Fizazi K, Frydenberg M, Gleave M, Halabi S, Heidenreich A, Higano CS, James N, Kantoff P, Kellokumpu-Lehtinen PL, Khauli RB, Kramer G, Logothetis C, Maluf F, Morgans AK, Morris MJ, Mottet N, Murthy V, Oh W, Ost P, Padhani AR, Parker C, Pritchard CC, Roach M, Rubin MA, Ryan C, Saad F, Sartor O, Scher H, Sella A, Shore N, Smith M, Soule H, Sternberg CN, Suzuki H, Sweeney C, Sydes MR, Tannock I, Tombal B, Valdagni R, Wiegel T, Omlin A.

Eur Urol. 2018 Feb;73(2):178-211. doi: 10.1016/j.eururo.2017.06.002. Epub 2017 Jun 24.

34.

Population-based study of grade progression in patients who harboured Gleason 3 + 3.

Sampurno F, Earnest A, Millar J, Frydenberg M, Murphy D, Delprado W, Evans S.

World J Urol. 2017 Nov;35(11):1689-1699. doi: 10.1007/s00345-017-2047-z. Epub 2017 May 12.

PMID:
28500489
35.

Reliability of negative multiparametric MRI of the prostate: can we avoid the biopsy? Not yet!

Frydenberg M.

BJU Int. 2017 May;119(5):E9-E10. doi: 10.1111/bju.13787. No abstract available.

36.

Systematic Review Links the Prevalence of Intraductal Carcinoma of the Prostate to Prostate Cancer Risk Categories.

Porter LH, Lawrence MG, Ilic D, Clouston D, Bolton DM, Frydenberg M, Murphy DG, Pezaro C, Risbridger GP, Taylor RA.

Eur Urol. 2017 Oct;72(4):492-495. doi: 10.1016/j.eururo.2017.03.013. Epub 2017 Mar 22. Review.

PMID:
28342640
37.

Expert consensus document: Semantics in active surveillance for men with localized prostate cancer - results of a modified Delphi consensus procedure.

Bruinsma SM, Roobol MJ, Carroll PR, Klotz L, Pickles T, Moore CM, Gnanapragasam VJ, Villers A, Rannikko A, Valdagni R, Frydenberg M, Kakehi Y, Filson CP, Bangma CH; Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) consortium.

Nat Rev Urol. 2017 May;14(5):312-322. doi: 10.1038/nrurol.2017.26. Epub 2017 Mar 14. Review.

38.

Germline BRCA2 mutations drive prostate cancers with distinct evolutionary trajectories.

Taylor RA, Fraser M, Livingstone J, Espiritu SM, Thorne H, Huang V, Lo W, Shiah YJ, Yamaguchi TN, Sliwinski A, Horsburgh S, Meng A, Heisler LE, Yu N, Yousif F, Papargiris M, Lawrence MG, Timms L, Murphy DG, Frydenberg M, Hopkins JF, Bolton D, Clouston D, McPherson JD, van der Kwast T, Boutros PC, Risbridger GP, Bristow RG.

Nat Commun. 2017 Jan 9;8:13671. doi: 10.1038/ncomms13671.

39.

Zero hospital admissions for infection after 577 transperineal prostate biopsies using single-dose cephazolin prophylaxis.

Pepdjonovic L, Tan GH, Huang S, Mann S, Frydenberg M, Moon D, Hanegbi U, Landau A, Snow R, Grummet J.

World J Urol. 2017 Aug;35(8):1199-1203. doi: 10.1007/s00345-016-1985-1. Epub 2016 Dec 16.

PMID:
27987032
40.

Trajectories of quality of life, life satisfaction, and psychological adjustment after prostate cancer.

Chambers SK, Ng SK, Baade P, Aitken JF, Hyde MK, Wittert G, Frydenberg M, Dunn J.

Psychooncology. 2017 Oct;26(10):1576-1585. doi: 10.1002/pon.4342. Epub 2017 Jan 11.

41.

Response to Dr Stevens' letter ref. Visitisen et al: "Short-term effects of night shift work on breast cancer risk: a cohort study of payroll data".

Kolstad HA, Garde AH, Hansen ÅM, Frydenberg M, Christiansen P, Vistisen HT, Bonde JP.

Scand J Work Environ Health. 2017 Jan 1;43(1):96. doi: 10.5271/sjweh.3609. Epub 2016 Dec 9.

42.

Mindfulness-Based Cognitive Therapy in Advanced Prostate Cancer: A Randomized Controlled Trial.

Chambers SK, Occhipinti S, Foley E, Clutton S, Legg M, Berry M, Stockler MR, Frydenberg M, Gardiner RA, Lepore SJ, Davis ID, Smith DP.

J Clin Oncol. 2017 Jan 20;35(3):291-297. doi: 10.1200/JCO.2016.68.8788. Epub 2016 Nov 21.

PMID:
27870567
43.

Short-term effects of night shift work on breast cancer risk: a cohort study of payroll data.

Vistisen HT, Garde AH, Frydenberg M, Christiansen P, Hansen ÅM, Andersen J, Bonde JP, Kolstad HA.

Scand J Work Environ Health. 2017 Jan 1;43(1):59-67. doi: 10.5271/sjweh.3603. Epub 2016 Nov 14.

44.

Re: Robot-assisted Laparoscopic Prostatectomy (RALP) Versus Open Radical Retropubic Prostatectomy (RRP): Early Outcomes from a Randomised Controlled Phase 3 Trial.

Frydenberg M.

Eur Urol. 2017 Mar;71(3):493-494. doi: 10.1016/j.eururo.2016.10.032. Epub 2016 Nov 9. No abstract available.

PMID:
27838172
45.

Impact of branding on public awareness of healthcare-related governing bodies: a pilot study of the Urological Society of Australia and New Zealand brand.

Gianduzzo TR, Gardiner RA, Rashid P, Young R, Frydenberg M, Kelly S.

BJU Int. 2016 Oct;118 Suppl 3:23-29. doi: 10.1111/bju.13469.

46.

Diagnostic and treatment factors associated with poor survival from prostate cancer are differentially distributed between regional and metropolitan Victoria, Australia.

Ruseckaite R, Sampurno F, Millar J, Frydenberg M, Evans S.

BMC Urol. 2016 Sep 2;16(1):54. doi: 10.1186/s12894-016-0172-4.

47.

Obesity does not promote tumorigenesis of localized patient-derived prostate cancer xenografts.

Lo JC, Clark AK, Ascui N, Frydenberg M, Risbridger GP, Taylor RA, Watt MJ.

Oncotarget. 2016 Jul 26;7(30):47650-47662. doi: 10.18632/oncotarget.10258.

48.

The role of mindfulness in distress and quality of life for men with advanced prostate cancer.

Chambers SK, Foley E, Clutton S, McDowall R, Occhipinti S, Berry M, Stockler MR, Lepore SJ, Frydenberg M, Gardiner RA, Davis ID, Smith DP.

Qual Life Res. 2016 Dec;25(12):3027-3035. Epub 2016 Jun 17.

49.

Risk of hypersensitivity pneumonitis and interstitial lung diseases among pigeon breeders.

Cramer C, Schlünssen V, Bendstrup E, Stokholm ZA, Vestergaard JM, Frydenberg M, Kolstad HA.

Eur Respir J. 2016 Sep;48(3):818-25. doi: 10.1183/13993003.00376-2016. Epub 2016 May 26.

50.

Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial.

Duchesne GM, Woo HH, Bassett JK, Bowe SJ, D'Este C, Frydenberg M, King M, Ledwich L, Loblaw A, Malone S, Millar J, Milne R, Smith RG, Spry N, Stockler M, Syme RA, Tai KH, Turner S.

Lancet Oncol. 2016 Jun;17(6):727-737. doi: 10.1016/S1470-2045(16)00107-8. Epub 2016 May 4. Erratum in: Lancet Oncol. 2016 Jun;17 (6):e223. Erratum in: Lancet Oncol. 2017 Sep;18(9):e510.

PMID:
27155740

Supplemental Content

Loading ...
Support Center